Papers in Future HIV Therapy
Page 1 · newest first
- Proposed Guidelines for the Prevention of Mother-To-Child Transmission of HIV in Middle-Income Countries: The Thai Red Cross Pmtct GuidelinesFuture HIV Therapy · 2008
- Self-Reported Low Physical Function is Associated with Diabetes Mellitus and Insulin Resistance in HIV-Positive and HIV-Negative MenFuture HIV Therapy · 2008
- Etravirine: A Second-Generation Nnrti for Treatment-Experienced Adults with Resistant HIV-1 InfectionFuture HIV Therapy · 2008
- Drug Resistance Differences Among HIV Types and Subtypes: A Growing ProblemFuture HIV Therapy · 2008
- Rnai as a Potential New Therapy for HIV InfectionFuture HIV Therapy · 2008
- The White and the Three-Letter Plague: Integration of TB and HIV Care in Sub-Saharan AfricaFuture HIV Therapy · 2008
- Update on the Development of HIV Entry InhibitorsFuture HIV Therapy · 2008
- Prophylaxis and Treatment of Malaria in HIV-Infected PopulationsFuture HIV Therapy · 2008
- Clinical Significance of HIV-Associated Bone Loss: When and How to InterveneFuture HIV Therapy · 2008
- Of Mice and Monkeys: New Advances in Animal Models to Study HIV-1 Therapy and ProphylaxisFuture HIV Therapy · 2008
- Transcriptional Gene Silencing as a Genetic Therapy for HIV-1Future HIV Therapy · 2008
- Cytotoxic T Lymphocyte Responses in HIV-1-Infected Long-Term Nonprogressors: Lessons for Vaccine DesignFuture HIV Therapy · 2008
- Oxidative Stress and HIV Infection: Target Pathways for Novel Therapies?Future HIV Therapy · 2008
- Different Disease Progression Rate According to HIV-1 SubtypeFuture HIV Therapy · 2008
- Modeling HIV Infection Dynamics: The Role of Recombination in the Development of Drug ResistanceFuture HIV Therapy · 2008
- Developing Neuroprotective Strategies for Treatment of HIV-Associated Neurocognitive DysfunctionFuture HIV Therapy · 2008
- Immune Restoration Disease Complicating Antiretroviral Therapy in Patients with HIV Infection: Implications and SolutionsFuture HIV Therapy · 2008
- Socs1: A Host Factor Required for HIV-1 Gag TraffickingFuture HIV Therapy · 2008
- When Should Antiretroviral Therapy Be Started for HIV-Infected Infants in Resource-Limited Settings?Future HIV Therapy · 2008
- Induction–Maintenance Therapy for HIV-1 InfectionFuture HIV Therapy · 2008
- Identifying Membrane Protein Surface Markers of HIV-1 InfectionFuture HIV Therapy · 2008
- Function and Polymorphisms of Anti-Hiv Host Factors: Evidence from Exposed Uninfected IndividualsFuture HIV Therapy · 2008
- Maraviroc: A Ccr5 AntagonistFuture HIV Therapy · 2008
- Darunavir: A New HIV-1 Protease Inhibitor for the Treatment of HIV InfectionFuture HIV Therapy · 2008
- Cardiovascular Risk and Choice of HIV Drug RegimenFuture HIV Therapy · 2007
- For-Profit Policies and Equitable Access to Antiretroviral Drugs in Resource-Limited CountriesFuture HIV Therapy · 2007
- Cytokine Findings in the CSF of HIV-Positive PatientsFuture HIV Therapy · 2007
- Effect of Host Genetic Variation on the Pharmacokinetics and Clinical Response of NnrtisFuture HIV Therapy · 2007
- Role of the HIV-1 Regulatory Protein NefFuture HIV Therapy · 2007
- Implications from the SIV Model in Understanding HIV NeutralizationFuture HIV Therapy · 2007
- Concurrent Drug Therapy for Tuberculosis and HIV Infection in Resource-Limited Settings: Present Status and Future ProspectsFuture HIV Therapy · 2007
- Host Genetic Variation and Susceptibility to Primate LentivirusesFuture HIV Therapy · 2007
- Host Cell Factors and HIV-1 IntegrationFuture HIV Therapy · 2007
- HIV-1 Gag TraffickingFuture HIV Therapy · 2007
- Targeting Protein–Protein Interactions for HIV TherapeuticsFuture HIV Therapy · 2007
- Strategies for the Optimal Sequencing of Antiretroviral Drugs Toward Overcoming and Preventing Drug ResistanceFuture HIV Therapy · 2007
- Non-Neutralizing Antibodies and Vaccine-Induced Protection Against HIVFuture HIV Therapy · 2007
- Biologically Active Coumarins as Inhibitors of HIV-1Future HIV Therapy · 2007
- Clinical Impact of HIV-1 Subtype: Are There Important Differences?Future HIV Therapy · 2007
- Busting a Gut Understanding HIV Pathogenesis in Lymphoid TissueFuture HIV Therapy · 2007
- Molecular Mechanisms of HIV-1 Resistance to Nucleoside and Nucleotide Reverse Transcriptase InhibitorsFuture HIV Therapy · 2007
- Important Considerations Regarding Antiretroviral Therapy in HIV-Positive WomenFuture HIV Therapy · 2007
- Microbicides in HIV PreventionFuture HIV Therapy · 2007
- Combined Use of Cytokines, Hormones and Therapeutic Vaccines During Effective Antiretroviral TherapyFuture HIV Therapy · 2007
- The Bull‘S-Eye for HIV Vaccine Development DefinedFuture HIV Therapy · 2007
- Treating Pregnant Women with Highly Active Antiretroviral TherapyFuture HIV Therapy · 2007
- Metabolic Complications of HIV Infection and Its Therapy in ChildrenFuture HIV Therapy · 2007
- Strategies for Targeting HIV-1 Envelope Glycoprotein Gp120 in the Development of New AntiviralsFuture HIV Therapy · 2007
- Nevirapine Prophylaxis for the Prevention of Perinatal HIV and the Impact of Resistance Mutations on Subsequent TherapyFuture HIV Therapy · 2007
- Development of Resistance After Administration of Single-Dose Nevirapine to Prevent Mother-To-Child Transmission of HIVFuture HIV Therapy · 2007